The New Heart Failure Association Definition of Advanced Heart Failure

Metra, Marco; Dinatolo, Elisabetta; Dasseni, Nicolò

doi:10.15420/cfr.2018.43.1

Cited by 26 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The alignment of the pathological drivers of heart failure with several beneficial mechanisms of the Mediterranean Diet are highly suggestive [118]. For example, oxidative stress is pathogenic in heart failure [118], and its mediators, such as oxidized low-density lipoprotein and its antibodies, are prognostic [119][120][121]; Mediterranean Dietary intervention reduced markers of inflammation [122]. Tuttolomondo et al, recently described how high-adherence to a Mediterranean-style diet was negatively correlated with presence of heart failure and with heart failure symptom severity, and is consistent with analysis performed by others [123,124].…”

Section: High-fat Diet and The Heartmentioning

confidence: 99%

Cardio-Metabolic Effects of High-Fat Diets and Their Underlying Mechanisms—A Narrative Review

et al. 2020

View full text Add to dashboard Cite

The majority of the epidemiological evidence over the past few decades has linked high intake of fats, especially saturated fats, to increased risk of diabetes and cardiovascular disease. However, findings of some recent studies (e.g., the PURE study) have contested this association. High saturated fat diets (HFD) have been widely used in rodent research to study the mechanism of insulin resistance and metabolic syndrome. Two separate but somewhat overlapping models—the diacylglycerol (DAG) model and the ceramide model—have emerged to explain the development of insulin resistance. Studies have shown that lipid deposition in tissues such as muscle and liver inhibit insulin signaling via the toxic molecules DAG and ceramide. DAGs activate protein kinase C that inhibit insulin-PI3K-Akt signaling by phosphorylating serine residues on insulin receptor substrate (IRS). Ceramides are sphingolipids with variable acyl group chain length and activate protein phosphatase 2A that dephosphorylates Akt to block insulin signaling. In adipose tissue, obesity leads to infiltration of macrophages that secrete pro-inflammatory cytokines that inhibit insulin signaling by phosphorylating serine residues of IRS proteins. For cardiovascular disease, studies in humans in the 1950s and 1960s linked high saturated fat intake with atherosclerosis and coronary artery disease. More recently, trials involving Mediterranean diet (e.g., PREDIMED study) have indicated that healthy monounsaturated fats are more effective in preventing cardiovascular mortality and coronary artery disease than are low-fat, low-cholesterol diets. Antioxidant and anti-inflammatory effects of Mediterranean diets are potential mediators of these benefits.

show abstract

Section: High-fat Diet and The Heartmentioning

confidence: 99%

Cardio-Metabolic Effects of High-Fat Diets and Their Underlying Mechanisms—A Narrative Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The decline of global cardiac function we observed in this study in C57BL/6J mice was significant but mild compared to clinical definitions of human heart failure both with reduced and preserved ejection fraction. 77 Other mouse strains may react with a more pronounced functional phenotype.…”

Section: Study Limitationsmentioning

confidence: 99%

Type 2 MI induced by a single high dose of isoproterenol in C57BL/6J mice triggers a persistent adaptive immune response against the heart

Forte

Panahi

Baxan

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Vascular intervention of peripheral arterial ischaemia (revascularisation, percutaneous transluminal angioplasty and/or stenting using physician reporting based of standard consensus definitions)28–32 (online supplementary appendix 5).…”

Section: Methods and Analysismentioning

confidence: 99%

“…Finally, analyses, using interaction terms, to identify important subgroups of participants (particularly suited for high-dose HDF or the reverse) will be undertaken. Prespecified subgroup analyses by age (<50, 50–65, >65 years), sex, residual renal function (<200 mL/day, 200–1000 mL/day and >1000 mL/day), diabetes, cardiovascular disease,26–30 a serum albumin ≤40 g/L, vascular access and dialysis vintage (<2 years, 2–5 years and >5 years) will be performed for exploratory purposes. Assumptions and fits of the statistical models will be evaluated using standard approaches.…”

Section: Methods and Analysismentioning

confidence: 99%

Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol

et al. 2020

View full text Add to dashboard Cite

IntroductionEnd-stage kidney disease (ESKD) is a major public health problem affecting more than 2 million people worldwide. It is one of the most severe chronic non-communicable diseases. Haemodialysis (HD) is the most common therapeutic option but is also associated with a risk of cardiovascular events, hospitalisation and suboptimal quality of life. Over the past decades, haemodiafiltration (HDF) has become available. Although high-dose HDF has shown some promising survival advantage compared to conventional HD, the evidence remains controversial. A Cochrane systematic review found, in low-quality trials, with various convective forms of dialysis, a reduction in cardiovascular, but not all-cause mortality and the effects on non-fatal cardiovascular events and hospitalisation were uncertain. In contrast, an individual patient data analysis suggested that high-dose HDF reduced both all-cause and cardiovascular mortality compared to HD. In view of these discrepant results, a definitive trial is required to determine whether high-dose HDF is preferable to high-flux HD. The comparison of high-dose HDF with high-flux HD (CONVINCE) study will assess the benefits and harms of high-dose HDF versus a conventional high-flux HD in adults with ESKD.Methods and analysisThis international, prospective, open label, randomised controlled trial aims to recruit 1800 ESKD adults treated with HD in nine European countries. Patients will be randomised 1:1 to high-dose HDF versus continuation of conventional high-flux HD. The primary outcome will be all-cause mortality at 3 years’ follow-up. Secondary outcomes will include cause-specific mortality, cardiovascular events, all-cause and infection-related hospitalisations, patient-reported outcomes (eg, health-related quality of life) and cost-effectiveness.Ethics and disseminationThe CONVINCE study will address the question of benefits and harms of high-dose HDF compared to high-flux HD for kidney replacement therapy in patients with ESKD with a focus on survival, patient perspectives and cost-effectiveness.Trial registration numberNetherlands National Trial Register (NTR 7138).

show abstract

The New Heart Failure Association Definition of Advanced Heart Failure

Cited by 26 publications

References 39 publications

Cardio-Metabolic Effects of High-Fat Diets and Their Underlying Mechanisms—A Narrative Review

Cardio-Metabolic Effects of High-Fat Diets and Their Underlying Mechanisms—A Narrative Review

Type 2 MI induced by a single high dose of isoproterenol in C57BL/6J mice triggers a persistent adaptive immune response against the heart

Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol

Contact Info

Product

Resources

About